

With Cirrhosis

TABLE 138: SVR GENOTYPE 4 WITH CIRRHOSIS TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	SOF12 + RBV12	1.47 (0.57 to 3.51)	27.52 (–27.44 to 66.40)
DCV24 + ASU24 + PR24		1.63 (1.00 to 3.81)	35.84 (–0.01 to 70.23)
DCV24 + ASU24 + PR24	SOF24 + RBV24	1.06 (0.71 to 2.99)	5.35 (–26.95 to 63.55)
Random effect model	Residual deviance	3.692 vs. 4 data points	
	Deviance information criteria	14.418	
Fixed effect model	Residual deviance	3.603 vs. 4 data points	
	Deviance information criteria	14.252	

ASU = asunaprevir; Crl = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.